The officially recommended dose (i.v.- 
however, no experimentally established dosing regimen was proposed. 6, 8, 9 The aim of the present two-phase study (see Methods section) was to define an adequate in-house lepirudin dosing-scheme for HIT patients with normal and variably decreased renal function. To the best of our knowledge this is the first study to propose lepirudin dosing regimens for HIT patients with normal, moderately and severely impaired renal function, thus providing evidence for reduced lepirudin doses, as recently recommended by the ACCP-panel. 2 For personal use only. on November 16, 2017 respectively) were treated with the in-house lepirudin dosage scheme derived from the results of the first study (see below). Table 2 summarizes relevant personal data, renal function and results of HIT work-up of both patient cohorts.
Retrospective investigational study
Lepirudin starting dose and anticoagulation intensity at first monitoring. (Table 3) . , respectively (Table 3 ).
In 9 patients with severely impaired renal function (CrCl < 30 ml/min) median lepirudin , respectively (Table 3 ).
The median lepirudin starting doses resulting in therapeutic anticoagulation intensity at first monitoring (i.e. 0.078, 0.040 and 0.013 mg kg -1 h -1 ) significantly differed among the three groups of HIT patients with normal, moderately or severely impaired renal function (p<0.001).
Duration and dose adjustments of lepirudin treatment.
The median duration of all lepirudin treatments was 7 (IQR: 4 -14; range: 1 -75) days.
During the whole treatment period we registered a median of 4 (IQR: 2 -8; range: 0 -16) dose adjustments per patient, 61 % of which were dose reductions. While treatment length was similar among all HIT patients independently from the initial anticoagulation intensity, the number of dose adjustments was lower among patients who were within therapeutic limits already at first monitoring (median 3, IQR: 1 -6, range: 0 -11) compared to those who were not (median 7, IQR: 3 -12, range: 0 -16; p=0.003). Dose adjustments where downwards in 60 % of patients within therapeutic range already at first monitoring, in 75 % of those who were initially over-anticoagulated and in 35 % of those with insufficient anticoagulation 4 hours after starting lepirudin (p<0.001). Table 3 displays initial and final lepirudin dosages among the different patient categories.
Efficacy of lepirudin starting dose.
The biological efficacy of omitting a bolus and using a reduced lepirudin starting dose was assessed by the course of platelet count and D-dimer values after initiation of the alternative anticoagulation. Figure 2A shows that the platelet count increased and normalised among the 31 patients who were within therapeutic range already at first monitoring despite reduced starting lepirudin dose. Moreover, D-dimer levels decreased in all 31 patients from a median of 4170 μg/l at HIT diagnosis to 1892 μg/l at follow-up, between day 2 and 5 ( Figure 2B ). For comparison, during the same time frame D-dimers decreased from median 5668 μg/l to 3322 μg/l in patients initially over-anticoagulated, while remained stable in those with initial sub-therapeutic anticoagulation (1888 μg/l versus 1612 μg/l).
Of note, among the 31 patients with therapeutic anticoagulation already at first monitoring, only one thromboembolic complication occurred during lepirudin treatment (Table 4, patient D). In this patient therapeutic anticoagulation with lepirudin was interrupted for several hours on two occasions: on day 5, for the placement of an intravenous catheter (complication diagnosed after this interruption: distal deep vein thrombosis of the left leg) and on day 7, for a suspected (but eventually not confirmed) intra-abdominal hemorrhage (complication diagnosed after the second interruption: massive pulmonary embolism).
We observed 3 additional thromboembolic complications while on lepirudin (Table 4) :
thrombosis of muscle-flap of the distal left lower leg after polytrauma leading to belowknee amputation on day 7; occlusion of a great saphenous vein by-pass in the context of a chronic peripheral arterial occlusive disease leading to amputation of the right leg on day 6; re-thrombosis of the right superficial femoral artery and truncus tibio-fibularis leading to below-knee amputation on day 4. All three patients were initially over-anticoagulated and experienced frequent dose reductions, including a total of 5 interruptions (each lasting at least 2 hours) among two of them; all three patients were still on lepirudin at time of amputation. Interestingly, no thromboembolic complications were observed among the 8 patients with an insufficient anticoagulation intensity at first control.
Bleeding during lepirudin treatment.
Overall, no fatal bleedings were observed. Seventeen out of 53 patients (32.1 %) required transfusion of packed red blood cells (RBC) during lepirudin treatment (Table 5) 
among those patients that were initially over-anticoagulated (28.6 %) compared to those with adequate starting dose (9.7 %). This is also reflected by a higher median number of packed RBC units administered per transfused patient (Table 5) . The biological efficacy of our in-house lepirudin dosage scheme is demonstrated on figure   3 , showing that the platelet count normalised in all three patient groups ( Figure 3A ) and that D-dimer levels decreased in all 15 patients from a median of 4874 μg/l at HIT (Table 5 ). The incidence of severe bleeding was 6.7 %, comparable to that observed among the 31 patients of the investigational cohort with adequate anticoagulation intensity already at the first control after lepirudin start (Table 5 ).
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The EMEA-and FDA-approved lepirudin dose for HIT patients (e.g., for patients with normal renal function administration of an 0.4 mg kg -1 bolus followed by a continuous intravenous infusion of 0.15 mg kg -1 h -1 , adjusted to maintain an aPTT 1.5 -2.5 times the baseline value) leads to over-anticoagulation. Recent publications have reported that lower doses may be sufficient. 6, 8, 9 In the present work we show that omission of the initial bolus and a reduced lepirudin Figures 2A and 3A) ; the D-dimer value decreased within 2-5 days (Figures 2B and 3B), demonstrating a dampening of the in vivo thrombin generation characteristic of acute HIT. 3 The rate of thrombotic complications observed during lepirudin treatment in the whole patient population is 5.9 % (4/68) and compares very well with the values of 11.2 % observed in the HAT-3 study 6 and of 13.8 % reported by the GEHT-HIT study group.
9
Of note, three out of the 4 thromboembolic complications occurred among patients who were initially overanticoagulated and required frequent dose-reductions ( HAT lepirudin studies. 6 In the present study, 4 of the 46 patients within therapeutic range already at first monitoring (8.7 %) required > 2 units packed RBC compared to 4/14 (28.6 %) of those who were initially over-anticoagulated (p=0.077) and median units of packed RBC administered per transfused patient were 2 compared to 5 (p=0.072, Table 5 ). In sum, among the HIT patients reported in this study, those with a therapeutic anticoagulation already at first monitoring appear to have less severe bleeding. This observation is in line with the data reported by the GEHT-HIT study group. 9 However, in countries were argatroban is available, this drug may represent a safer treatment option for HIT patients with severe renal failure because its elimination is mainly hepatobiliary. (Table 1) suggests that a plasma lepirudin concentration close to 0.50 μ g/ml is sufficient to achieve an adequate anticoagulation in HIT patients. This is about 1/3 of the upper limit of the therapeutic range (0.15 -1.50 μ g/ml) reported in the lepirudin product information leaflet and at the lower limit of the therapeutic concentration (0.6 -1.0 μg/ml) reported by Greinacher and Warkentin. 4 Among the investigational patient cohort, there was a significant dose reduction from a median starting dose of 0.078 mg kg -1 h -1 to a final one of 0.034 mg kg -1 h -1 in patients with normal renal function who were within therapeutic ranges since first monitoring Table 3 ).
This might be explained by the development of antibodies decreasing lepirudin clearance dosages may be required in the course of HIT treatment and that lepirudin dose should be assessed daily by clotting assays and course of platelets and D-dimers.
In conclusion, we show that omission of the initial bolus and a starting lepirudin dose of 0.08 mg kg -1 h -1 for HIT patients with normal renal function (CrCl > 60 ml/min), 0.04 mg kg -1 h -1 for those with moderately impaired renal function (CrCl 30 -60 ml/min) and 0.01 -0.02 mg kg -1 h -1 for those with CrCl < 30 ml/min is an efficacious treatment of the prothrombotic state of acute HIT and appears to be associated with a less severe bleeding tendency as compared to that induced by the officially recommended lepirudin dosage.
Our proposal is in line with the recently published ACCP-guideline; 2 however, with some differences: the ACCP-panel stratifies renal function by serum creatinine only and for patients with normal and moderately reduced renal function recommends slightly higher lepirudin doses as we report. Full validation of our proposed regimen will require appropriately designed multi-center studies. For For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
